Loading...
Docoh

Haemonetics (HAE)

Haemonetics is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services.

Company profile

Ticker
HAE
Exchange
CEO
Christopher Simon
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
5D Information Management, Inc. • Arryx, Inc. • Cardiva Medical, Inc. • Enicor GmbH • Global Med Technologies, Inc. • Haemonetics (Hong Kong) Limited • Haemonetics (UK) Limited • Haemonetics Asia Incorporated • Haemonetics Asia UK Ltd. • Haemonetics Australia PTY Ltd. ...
IRS number
42882273

HAE stock data

Calendar

25 May 22
12 Aug 22
2 Apr 23
Quarter (USD) Apr 22 Jan 22 Oct 21 Jul 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Apr 22 Apr 21 Mar 20 Mar 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
5 Aug 22 Abernathy Robert E Common Stock Grant Acquire A No No 0 2,730 0 17,855
5 Aug 22 Burzik Catherine M Common Stock Grant Acquire A No No 0 2,730 0 19,545
5 Aug 22 Coyle Michael J Common Stock Grant Acquire A No No 0 2,730 0 8,268
5 Aug 22 Charles J Dockendorff Common Stock Grant Acquire A No No 0 2,730 0 28,130
5 Aug 22 Johnson Lloyd Emerson Common Stock Grant Acquire A No No 0 2,730 0 5,807
99.8% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 239 257 -7.0%
Opened positions 28 57 -50.9%
Closed positions 46 45 +2.2%
Increased positions 96 88 +9.1%
Reduced positions 83 79 +5.1%
13F shares Current Prev Q Change
Total value 3.23B 2.67B +21.1%
Total shares 51.2M 50.34M +1.7%
Total puts 27.6K 70.2K -60.7%
Total calls 50.46K 292.9K -82.8%
Total put/call ratio 0.5 0.2 +128.2%
Largest owners Shares Value Change
Wellington Management 6.17M $389.78M +21.5%
BLK Blackrock 5.95M $376.27M -11.1%
Capital Research Global Investors 5.45M $344.68M +166.1%
Vanguard 4.91M $310.4M +0.6%
ATAC Neuberger Berman 3.77M $238.24M -2.8%
STT State Street 1.73M $109.66M +2.6%
BEN Franklin Resources 1.47M $93.01M +0.3%
Fisher Asset Management 1.19M $75.12M -0.5%
London Co Of Virginia 971.01K $61.39M +5.8%
LGT Capital Partners 966.5K $61.1M -20.5%
Largest transactions Shares Bought/sold Change
Capital Research Global Investors 5.45M +3.4M +166.1%
Wellington Management 6.17M +1.09M +21.5%
Armistice Capital 0 -872K EXIT
BLK Blackrock 5.95M -740.62K -11.1%
Westfield Capital Management 552.31K -735.37K -57.1%
JHG Janus Henderson 10.32K -433.55K -97.7%
Norges Bank 0 -381.77K EXIT
Balyasny Asset Management 0 -355.13K EXIT
FHI Federated Hermes 462.59K +320.18K +224.8%
Emerald Advisers 267.55K +267.55K NEW

Financial report summary

?
Competition
TerumoPanacea Life Sciences
Management Discussion
  • Our principal operations are in the United States, Europe, Japan and other parts of Asia. Our products are marketed in approximately 90 countries around the world through a combination of our direct sales force and independent distributors and agents.
  • International sales are generally conducted in local currencies, primarily Japanese Yen, Euro, Chinese Yuan and Australian Dollar. Our results of operations are impacted by changes in foreign exchange rates, particularly in the value of the Yen, Euro and Australian Dollar relative to the U.S. Dollar. We have placed foreign currency hedges to mitigate our exposure to foreign currency fluctuations.
  • Please see the section entitled “Foreign Exchange” in this discussion for a more complete explanation of how foreign currency affects our business and our strategy for managing this exposure.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: aforementioned, app, atrial, biometric, BIPA, boosting, cessation, circuit, complaint, contrary, Cook, County, Crumpton, debating, denied, depressed, discharge, divest, efficacy, eQue, equitable, fibrillation, fifteen, finger, freedom, guard, hybrid, inflationary, lawsuit, lessor, Mary, membership, merit, MidCap, milestone, military, motion, plaintiff, print, protectionist, qualitative, Rika, sanitation, scan, scanner, semiconductor, server, situated, situation, sponsorship, stay, stewardship, Swexit, UK, Ukraine, vaccine, Women
Removed: anti, BEAT, comparability, comparative, Cora, deductibility, deduction, disclosing, doubt, earliest, exclude, FDII, February, freeing, freely, geography, HDC, heavily, importation, LLC, media, negotiate, nondeductible, opposed, package, principle, reallocated, receipt, reorganized, small, sourced, spending, thereunder, turnaround, updated

Patents

Utility
Method for hemostasis testing
9 Aug 22
A sample testing cartridge is usable to perform a variety of tests on a viscoelastic sample, such hemostasis testing on a whole blood or blood component sample.
Utility
Thrombelastography device, heating apparatus, blood coagulation analysis system and rotational angle measurement method
21 Jun 22
A thrombelastography device, a heating apparatus, a blood coagulation analysis system, and a rotational angle measurement method are disclosed.
Utility
Methods and Devices for the Enrichment of Immunoglobulin from Blood
21 Apr 22
In some embodiments, the invention provides a method for extracting at least 55% of immunoglobulin such as IgG present in a biological fluid from the biological fluid, comprising contacting a biological fluid suspected of containing immunoglobulin with a solid support covalently bonded to a ligand that specifically binds to immunoglobulin under conditions sufficient for non-covalent binding of immunoglobulin to the ligand; and contacting the solid support with an elution solution under condition whereby the non-covalently bound immunoglobulin is released from the ligand and into the elution solution, wherein at least 55% of the IgG present in the biological fluid is extracted into the elution solution.
Utility
System and Method For Measuring Pressure of Fluid Flow
17 Feb 22
An apparatus for measuring pressure within a fluid path includes a housing defining the structure of the apparatus.
Utility
System and Method for Plasma Donor Engagement
25 Nov 21
A method for engaging a donor includes receiving, in a sewer, donor information and donation data for the donor, and sending a first communication to the donor.